Regulatory Outlook and Patient Interest in Sub-Q Anti-CD38 in Myeloma

Sikander Ailawadhi, MD, of the Mayo Clinic Florida in Jacksonville, discusses the current regulatory landscape and the significant anticipation surrounding the subcutaneous (SC) on-body injector (OBI) formulation of isatuximab (Sarclisa). Following the successful results of the IZALCO (NCT05704049) and IRAKLIA (NCT05405166) trials, the focus has shifted toward making this delivery method available in clinical practice. The transition from intravenous (IV) to OBI-based administration represents a fundamental shift in how immunotherapy is delivered and experienced by patients with multiple myeloma.

Regulatory Status and Clinical Success Rates

The European Medicines Agency (EMA) has already reviewed the data for the SC isatuximab OBI very favorably. This positive reception is based on a robust set of clinical findings, including a success rate of over 99% in accurately delivering the medication. Clinical trials reported high satisfaction levels not only from patients but also from medical staff, who benefit from reduced chair time and simplified logistics. The formulation met non-inferiority end points, proving that the move to a more convenient delivery method does not compromise the drug's clinical benefit.

In the United States, the device and formulation are currently under review by the FDA. Ailawadhi expresses optimism that the FDA will mirror the EMA’s favorable outlook, potentially approving the SC OBI for use across various isatuximab-based treatment regimens.

The Patient Perspective: A Revolutionary Shift

Perhaps the most significant aspect of this development is the intense interest from the patient community. Ailawadhi notes that in discussions with patient support groups and advocacy organizations, the potential for self-administration is viewed as a game-changer. Although clinicians are excited about the technical and pharmacological success of the OBI, the excitement from patients is rooted in the reduction of the patient burden. Although it needs additional study in the US, self-administration with the OBI could be the next stage for this therapy.

The prospect of self-administering a potent immunotherapy represents a very different way of managing cancer. For patients, this technology signifies a move away from the clinical setting as the sole site of care, allowing for a more flexible life that isn't tethered to an infusion center. If approved, the SC isatuximab OBI would represent a major step forward in patient-centric oncology, turning a complex medical procedure into a manageable part of a patient’s daily routine.